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Abstract
Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and bio-
chemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, 
are particularly important. ANGPTL3, 4 and 8 have been shown to regulate triglyceride availability 
depending on the nutritional status of the body. In addition, a deficiency of these proteins has been found 
to cause hypolipidemia (reduction of all lipid fractions). Increases in ANGPTL3, 4 and 8 appear to be 
associated with cardiovascular risk. Animal studies indicate that the use of ANGPTL3 (evinacumab) 
inhibitors significantly reduces plasma total cholesterol, triglycerides and low-density lipoprotein con-
centrations. The use of evinacumab in clinical trials also led to the normalization of plasma lipid con-
centrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. 
The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid 
disorders, especially those with hypertriglyceridemia. (Cardiol J)
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Angiopoietin-like proteins: Structure, 
function of lipid metabolism regulation
Interest of angiopoietin-like proteins (ANG-
PTL) in the context of lipid disorders treatment, 
especially in the treatment of hypertriglyceridemia, 
results from their multidirectional influence on the 
regulation of the lipid metabolism [1].
So far, 8 proteins belonging to the family of ANG - 
PTL1–ANGPTL8 have been discribed. ANGPTL 
are members of the vascular endothelial growth 
factor (VEGF) family. All ANGPTLs have a similar 
structure. The exception is ANGPTL8 which does 
not have a fibrinogen-like domain at the carboxy 
terminus [2]. These proteins are involved in stem 
cell expansion, inflammation regulation, tissue 
remodeling and angiogenesis [3, 4]. ANGPTL3, 
ANGPTL4 and ANGPTL8 are primarily involved 
in lipid metabolism (Fig. 1) [1, 5].
ANGPTL3 is a glycoprotein synthesized main-
ly by the liver and kidneys. Biological activation of 
ANGPTL3 occurs intra- and extracellularly. About 
50% of the ANGPTL3 precursor form produced 
is proteolytically cleaved in the cell with furin 
(this enzyme also participates in the activation of 
natriuretic peptides) to a form with greater biologi-
cal activity. The remaining 50% of the precursor 
form ANGPTL3 is secreted into the extracellular 
space, where it may undergo proteolytic cleavage 
by furin or proprotein convertase subtilisin/kexin 
type 6 (PCSK6). As a result of the action of furin 
or PCSK6, the N-terminal domain capable of inhib-
iting lipoprotein lipase (LPL) activity is exposed 
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form ANGPTL3 [6]. ANGPTL3 circulates in both 
forms in the plasma [6]. In addition, it is known 
that other enzymes, such as PCSK2, PCSK4, 
PCSK5 and PCSK7, can also catalyze the proteo-
lytic cleavage of the ANGPTL3 precursor form [3]. 
Interestingly, it has been shown that ANGPTL3 
cleavage appears to be facilitated by ANGPTL8 
(lipasin). ANGPTL8 is secreted by the liver into 
the circulation, where it interacts with ANG-
PTL3 for cleavage and forms a complex with the 
N-terminal fragment of ANGPTL3. The complex, 
like the free N-terminal fragment of ANGPTL3 
[7]. Formation of the ANGPTL8-ANGPTL3 com-
plex induces structural changes in ANGPTL8 that 
reveal a motif that inhibits LPL inhibition. Thus, 
ANGPTL8 remains inactive until it forms a com-
plex with ANGPTL3. Furthermore, the ability of 
the ANGPTL8/ANGPTL3 complex to inhibit LPL 
is known to depend on the active LPL inhibitory 
motif in ANGPTL8 [8]. This is confirmed by the 
observations that LPL inhibition by the ANGPTL3/ 
/ANGPTL8 complex could not be reversed by the 
anti-ANGPTL3 blocking antibody [8]. The factors 
regulating ANGPTL3 transcription are LXR (liver 
X receptors) and nuclear factor 1 hepatocyte alpha 
(HNF-1a) [9]. In an interesting study by Foka et al. 
[10] showed that ANGPTL3 is negatively regulated 
by hepatitis C virus (HCV) in vivo and in vitro. 
The HCV core suppresses ANGPTL3 expression 
by loss of HNF-1a binding activity and blocking 
LXR/RXR (retinoid X receptor) transactivation. 
The presumed resulting increase in serum lipid 
clearance and uptake by the liver may support HCV 
replication and persistence [10].
ANGPTL4 is a glycoprotein synthesized by 
many tissues, including adipose tissue, liver, 
intestines and muscles [11]. The expression of 
the ANGPTL4 gene is regulated by hunger and 
satiety. In particular, starvation enhances ANG-
PTL4 expression [1]. In addition, ANGPTL4 gene 
expression is also stimulated by receptor ligands 
activated by peroxisome proliferators (PPAR-a, 
-d and g) [11]. 
It is known that ANGPTL3, ANGPTL4 and 
ANGPTL8, like C-III apolipoprotein, reduce LPL 
activity to varying degrees [1]. The basic function 
of LPL is the hydrolysis of triacylglycerols (TG) 
transported in chylomicrons and very low-density 
lipoproteins (VLDL). As a result, residual chy-
lomicrons (so-called chylomicron remnants) and 
intermediate density lipoproteins (IDL), which are 
precursors of low-density lipoproteins (LDL), are 
formed (Fig. 2) [12, 13].
ANGPTL3 reduces plasma VLDL and chy-
lomicrons concentrations by reducing LPL ac-
tivity and promoting lipolysis in adipose tissue. 
Furthermore, ANGPTL3 has been shown to 
reduce endothelial lipase (EL) activity [14]. This 
enzyme performs similar functions to LPL. It 
is known that EL is synthesized by endothelial 
cells and has antiatherosclerotic properties. EL 
catalyzes the hydrolysis reaction of phospholipids 
contained in high-density lipoproteins (HDLs), 
which increases the rate of HDL circulation, 
Figure 1. Schematic representation of the structure of angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, 
and ANGPTL8). Based on [1, 5]; EL — endothelial lipase; LPL — lipoprotein lipase; LR — linker region; SE1 region — 
specific epitope 1.
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which leads to a decrease in plasma cholesterol 
concentration [15]. To date, however, the mecha-
nism by which ANGPTL3 reduces LPL activity 
is not fully understood [1]. As indicated by Liu et 
al. [16] ANGPTL3 may increase LPL cleavage by 
endogenous furin and PACE4, but not by PCSK5. 
This mechanism is specific for LPL, but not for 
EL. Moreover, ANGPTL3 enhances LPL cleavage 
in the presence of either heparan sulfate proteo-
glycans or glycosylphosphatidylinositol-anchored 
high-density lipoprotein-binding protein 1 (GPI-
HBP1). By enhancing LPL cleavage, ANGPTL3 
dissociates LPL from the cell surface, inhibiting 
both the catalytic and noncatalytic functions of 
LPL [16]. Another potential mechanism of action 
of ANGPTL3 is to promote TG accumulation in 
adipocytes [17]. Chi et al. [18] found that ANG-
PTL4 by attaching to LPL reduces its affinity for 
GPIHBP1. The biological function of ANGPTL8 
is dependent on ANGPTL3 and also consists in 
reducing LPL stimulation [19]. 
Kovrov et al. [20] showed that ANGPTL3, 
ANGPTL4 and ANGPTL8 reduce LPL activity by 
causing its cleavage from dimeric (biologically ac-
tive) to monomeric (biologically inactive) [20, 21].
The main physiological role of ANGPTL3, 
ANGPTL4 and ANGPTL8 resulting from the re-
duction of LPL excitation is the regulation of TG 
distribution (Fig. 3) [22].
During fed, ANGPTL3 and ANGPTL8 promote 
TG deposition in white adipose tissue by specifi-
cally inhibiting LPL activity in oxidative tissues 
(heart, skeletal muscle and brown adipose tissue). 
During exercise, starvation, and exposure to low 
temperatures, ANGPTL4 inhibits local LPL activ-
ity in white adipose tissue to provide sufficient 
energy to the heart, skeletal muscles, and brown 
adipose tissue (Fig. 3) [1, 23]. ANGPTL8 sup-
Figure 2. Participation lipoprotein lipase (LPL) in lipoprotein metabolism. Based on [13]; apoC-II — apolipoprotein C-II; 
FFA — free fatty acids; Gly — glycerol; GPIHBP1 — glycosylphosphatidylinositol anchored high density lipoprotein 
binding protein 1; HDL — high-density lipoprotein; IDL — intermediate-density lipoprotein; TG — triacylglycerols; 
VLDL — very low-density lipoprotein.
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pression during fasting is mediated by increased 
glucocorticoid levels and their binding to negative 
glucocorticoid responsive elements in the promo-
tor region [24].
In summary, ANGPTL3, ANGPTL4 and 
ANGPTL8 together ensure that triglycerides from 
triglyceride-rich lipoproteins are properly distrib-
uted under various physiological conditions [22].
ANGPTL3, 4 and 8 and cardiovascular 
risk: Observational studies
In a study by Morinaga et al. [25] involving 988 
Japanese, ANGPTL3, 4 and 8 serum concentration 
and cardiovascular risk were analyzed. ANGPTL 
serum concentration measurement by enzyme-
-linked immunosorbent assay. Serum ANGPTL3 
concentrations have been shown to be relatively 
high in patients with hepatic impairment and 
inflammation. Serum ANGPTL4 concentrations 
were also significantly increased in patients with 
impaired glucose metabolism, liver failure, but 
decreased in inflammation. In addition, an increase 
in serum ANGPTL8 concentration was observed in 
patients with glucose metabolism disorders, obe-
sity and dyslipidemia. In particular, the increased 
ANGPTL8 serum concentration was positively 
correlated with serum triglyceride and LDL choles-
terol concentration and inversely correlated with 
serum HDL cholesterol concentration. Therefore, 
it was found that the concentration of ANGPTL3, 
4 and 8 in serum reflects the occurrence of some 
Figure 3. Lipid partitioning by angiopoietin-like proteins (ANGPTL). Based on [23]; FFA — free fatty acids; Gly — glic-
erol; GPIHBP1 — glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1; LPL — lipoprotein 
lipase; TG — triacylglycerols; VLDL — very-low density lipoprotein.
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risk factors for the development of cardiovascular 
diseases [25]. In a study by Dewey et al. [26], the 
effect of ANGPTL3 gene polymorphism on triglyc-
erides, LDL and HDL serum concentrations were 
analyzed. We sequenced the ANGPTL3 exons 
in 58.335 participants of the DiscovEHR human 
genetics study. Association tests for variants of 
loss of function in ANGPTL3 with lipid serum 
concentration and coronary artery disease (CAD) 
were carried out in 13.102 patient cases and 40.430 
controls from the DiscovEHR study, with further 
studies involving 23.317 patient cases and 107.166 
patients from four population studies. It was shown 
that people who were heterozygous in terms of 
loss of function in ANGPTL3 had significantly 
decreased triglycerides, HDL and LDL serum 
concentrations (Fig. 4) [26].
Moreover, it was found that people heterozy-
gous for loss of ANGPTL3 gene function were 
characterized by a less incidence of cardiovascular 
disease (Fig. 5) [26].
Sitiziel et al. [27] assessed the effect of ANG-
PTL3 deficiency on CAD risk. Three subjects 
with total ANGPTL3 deficiency were included 
in the study. In the population mutations of loss 
of ANGPTL3 function (LOF) were found in up 
to 21.980 subjects with CAD and 158.200 control 
subjects. LOF mutations were defined as nonsense 
variants, frame shift and splice site, along with mis-
sense variants giving < 25% wild type ANGPTL3 
activity in the mouse model. The biomarker study 
measured circulating ANGPTL3 in 1493 subjects 
with myocardial infraction and 3232 controls. It 
was shown that subjects with complete ANGPTL3 
deficiency did not have coronary plaque. Sequenc-
ing of the ANGPTL3 genes showed that about 1 in 
309 people were heterozygous carriers of the LOF 
mutation. Compared with those without mutations, 
heterozygous carriers of the ANGPTL3 LOF mu-
tation showed a 17% reduction in circulating TG 
and a 12% reduction in LDL. The carrier’s status 
was associated with a 34% decrease in the CAD 
chance. People with the lowest tertile in circulating 
ANGPTL3 concentrations, compared to the high-
est, had a reduced chance of myocardial infraction 
(Fig. 6) [27].
The results of these observational studies 
indicate that increased ANGPTL3, 4 and 8 may 
be associated with increased cardiovascular risk 
[25–27].
ANGPTL inhibitors: Experimental  
and pre-clinical studies
In 2002, Koishi et al. [28] identified an inser-
tional mutation ANGPTL3 gene associated with 
hypolipidemic phenotype in obese knockout mice 
(KK/San mice). TG, total cholesterol and free fatty 
acids plasma concentrations in these mice were 
lower than in wild-type mice [28]. These observa-
tions were confirmed in the studies of Shimamura 
et al. [29, 30] in which wild-type KK mice showed 
signs of obesity accompanied by hyperinsulinemia 
and hypertriglyceridemia. The mutant strain of 
mice (KK/San and KK/Snk; mice expressing trun-
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Figure 4. Associations between angiopoietin-like protein 3 (ANGPTL3) predicted loss-of-function variants and lipid 
serum concentrations in DiscovEHR Study participants. Based on [26]; HDL — high density lipoprotein; LDL — low 
density lipoprotein.
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and diabetes with a > 90% lower TG plasma con-
centration compared to wild-type mice. Administra-
tion of adenovirus with the normal ANGPTL3 gene 
to mutated mice resulted in increased TG plasma 
concentrations. To explain the effect of ANG - 
PTL3 on TG metabolism, overexpression of the 
ANGPTL3 gene was induced in mice. Increases in 
plasma total cholesterol, non-esterified fatty acids, 
as well as TG-rich lipoproteins concentrations have 
been observed. Subsequent studies affirmed that 
there was no significant difference between mutant 
and wild-type KK mice in the hepatic VLDL TG 
secretion rate, but in vitro analysis of recombinant 
protein revealed that ANGPTL3 directly inhib-
ited LPL activity [29, 30]. It was shown that the 
removal of the ANGPTL3 gene in mice increased 
LPL activity by approximately 1.6× compared to 
wild-type mice [31]. The same experimental model 
showed a significant fall in the uptake of circulat-
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Figure 6. Association of angiopoietin-like protein 3 (ANGPTL3) plasma concentration with myocardial infarction risk. 
















































Figure 5. Association of angiopoietin-like protein 3 (ANGPTL3) loss of function (LOF) variants and coronary artery 
disease (CAD). Based on [26]; CI — confidence interval; GHS — Geisinger Health System (DiscovEHR study); CGPS 
— Copenhagen General Population Studies; Penn — Penn the University of Pennsylvania Medicine BioBank; Duke — 
Duke Catheterization Genetics cohort; TAICHI — Taiwan Metabochip consortium.
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than into skeletal muscle, brown adipose tissue 
and heart [32].
Thus, in experimental studies it was found that 
the lack of ANGPTL3 leads to a decrease plasma 
TG, total cholesterol, free fatty acids, VLDL, LDL 
and apoB100 concentrations [1].
Because genetic studies indicate that ANG- 
PTL3 deficiency protects against atherosclerosis 
and that this is a causal relationship, work is ongo-
ing on the anti-ANGPTL3 antibody (evinacumab).
Evinacumab (REGN1500) is a fully human 
monoclonal antibody (mAb) against ANGPTL3. 
This drug was developed by Regeneron Pharma-
ceuticals, and on April 6, 2017, the United States 
Food and Drug Administration (FDA) recognized 
evinacumab as a breakthrough therapy in the 
treatment of hypercholesterolemia in patients 
with homozygous familial hypercholesterolemia 
(HoFH). Evinacumab can be administered subcu-
taneously (sc) or intravenously (iv). The formation 
of the evinacumab-ANGPTL3 complex reduces the 
biological activity of ANGPTL3 (Fig. 7) [33, 34].
In a study by Wang et al. [35] using evinacumab 
in mice with a genetic deficiency in key proteins 
involved in the clearance of apoB100 containing 
lipoproteins, it was shown that evinacumab treat-
ment consistently reduced plasma total cholesterol 
concentrations in mice in which apoE, receptor 
LDL, Lrp1 and Sdc1 were inactivated alone or in 
combination. Despite a 61% reduction in VLDL-TG 
production, production of VLDL-apoB100 did not 
change in evinacumab-treated animals. Hepatic TG 
content, fatty acid synthesis and fatty acid oxidation 
were similar in evinacumab and antibody treated 
control animals. In summary, researchers state 
that inactivation of ANGPTL3 does not affect the 
number of apoB100-containing lipoproteins secreted 
by the liver, but changes the produced particles 
in such a way that they are removed faster from 
the circulation [35]. Another study looked at the 
Figure 7. Mechanism of action of evinacumab and ANGPTL3-LRx. Based on [34]; ANGPTL3 — angiopoietin-like protein 3; 
ANGPTL3-LRx — antisense oligonucleotide; ASGPR — asialoglycoprotein receptor.
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effect of administration of evinacumab that binds 
ANGPTL3 with high affinity to the lipid profile 
in normolipemic mice. Evinacumab reversed 
ANGPTL3-induced inhibition of LPL activity in 
vitro. Intravenously evinacumab administration 
of C57Bl/6 normolipidemic mice increased LPL 
activity and decreased plasma TG concentrations 
by ≥ 50%. In addition, chronic administration of 
evinacumab to C57Bl/6 dyslipidemic mice for 
8 weeks reduced plasma TG, LDL and HDL con-
centrations without any change in liver, fat or heart 
TG content. Studies in EL KK mice revealed that 
evinacumab reduced serum HDL concentration via 
an EL-dependent mechanism. Finally, administra-
tion of a single dose of evinacumab to dyslipidemic 
cynomolgus monkeys resulted in a rapid and pro-
nounced decrease plasma TG, non-HDL and HDL 
concentration. Evinacumab normalized plasma 
TG concentration even in monkeys with baseline 
plasma TG concentration greater than 400 mg/dL 
[36]. Pouwer et al. [37] studied the effect of such 
lipid lowering interventions on atherosclerosis 
in APOE*3-Leiden. CETP mice, a well-estab-
lished model of hyperlipidemia. The mice were fed 
a Western-type diet for 13 weeks and then matched 
to the basal group (died after 13 weeks) and five 
groups who received the diet alone (control) or with 
treatment (atorvastatin; atorvastatin and alirocum-
ab; atorvastatin and evinacumab; or atorvastatin, 
alirocumab and evinacumab [triple therapy]) for 
25 weeks. The impact of the intervention on choles-
terol plasma concentration, plaque composition and 
morphology, monocyte adhesion and macrophage 
proliferation were analyzed. All interventions re-
duced total plasma cholesterol concentration (37% 
with atorvastatin to 80% with triple treatment; all 
p < 0.001). Triple treatment reduced non-HDL to 
1.0 mmol/L (91% difference compared to control; 
p < 0.001). Atorvastatin reduced the progression 
of atherosclerosis by 28% compared to control 
(p < 0.001); double treatment completely blocked 
the progression and reduced the severity of the 
lesions. Triple treatment reduced the size of the 
lesion compared to baseline in the thoracic aorta 
by 50% and aortic root by 36% (both p < 0.05 com-
pared to baseline), reduced macrophage accumu-
lation through reduced proliferation, and reduced 
the severity of the lesion. Thus, triple cholesterol-
lowering therapy, targeted at all apoB100-containing 
lipoproteins, regresses the area of atherosclerotic 
lesions and improves the composition of the lesions 
in mice [37]. In another interesting study, Graham 
et al. [38] evaluated the effect of the use of ANG-
PTL3 antisense oligonucleotides (ASO) on the lipid 
profile of mice with knockout of the LDL receptor 
(LDL-R–/–), double-knockout mice (ApoC-III–/– and 
LDL-R–/–), heterozygous mice (ApoCIII+/– and 
LDL-R–/–), mice with diet-induced obesity, and mice 
overexpressing human apolipoprotein C-III. The 
administration of murine ANGPTL3 ASO has been 
shown to lead to a decrease in ANGPTL3 mRNA 
expression from 69% to 91%, which corresponds 
to a reduction in protein levels 50–90% in each of 
these mouse models. For lipid profile, TG, LDL and 
HDL were reduced, between 35–85%, 7–64% and 
3–23%, respectively. Importantly, ANGPTL3-LRx 
also reduces liver TG secretion, which suggests 
that an ANGPTL3 targeted drug could be used to 
treat fatty liver [38]. Other studies on wild-type 
and hyperlipemic LDL-R–/– mice, in which the 
ANGPTL3 gene was edited using the CRISP-Cas9 
(clustered regularly-interspaced short palindromic 
repeats) method, showed a decreased plasma TG 
and total cholesterol concentration by 31% and 19% 
and 56%, and 51%, respectively [39].
Interestingly, the use of anti-ANGPTL4 mono-
clonal antibody (anti-ANGPTL4 mAb) on high-fat 
diet fed mice led to decrease TG concentration by 
50% and 59%, and total cholesterol by 30%. In the 
LDL-R–/– or db/db group of mice, this intervention 
led to decrease plasma TG concentration by 55% 
and total cholesterol by 25%. In the apoE–/– mouse 
group, no changes in lipid profile were observed [40].
Less interest in ANGPTL4 as a therapeutic 
target is due to reported adverse effects such as 
mesenteric adenitis in rodents treated with anti-
-ANGPTL4 antibody [41].
ANGPTL inhibitors: Clinical studies
Evinacumab
The first phase double-blind, placebo-con-
trolled clinical study evaluated the safety and effi-
cacy of sc or iv evinacumab in patients with elevated 
TG (150) ≤ TG ≤ 450 mg/dL) and/or LDL (≥ 100 
mg/dL). In this study randomized participants to 
placebo (9, PBO sc; 12, PBO iv) and evinacumab (11, 
75 mg sc; 12, 150 mg sc; 9, 250 mg sc; 10, 5 mg/kg 
iv; 9, 10 mg/kg iv; 11, 20 mg/kg iv). Evinacumab 
was shown to be well tolerated in the study. The 
most common adverse reaction was headache 
(11.3% in the evinacumab group). There was no 
dose related safety trend. Evinacumab caused 
a dose-dependent reduction plasma TG concentra-
tion by 1.0% to 75.0% and LDL by 3.4% to 25.5%. 
A dose-dependent decrease plasma HDL, VLDL, 
total cholesterol, non-HDL cholesterol, ApoA1 and 
ApoB100 concentrations was also observed, but 
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no apparent effect on Lp(a) [42]. Similar results 
were obtained in the study by Dewey et al. [26] 
83 volunteers with mild to moderately elevated tri-
glycerides (150 to 450 mg/dL) or LDL cholesterol 
(≥ 100 mg/dL) were included in the study. It was 
shown that the maximum changes in lipid plasma 
concentrations found in patients who received 
the 20 mg iv dose per kilogram were as follows: 
TG — 76.0% (day 4); directly measured LDL — 
23.2% (day 15); and HDL — 18.4% (day 15) [26]. 
Ahmad et al. [43] evaluated the effect of admin-
istering evinacumab in patients with TG > 150 
but ≤ 450 mg/dL and LDL cholesterol ≥ 100 mg/dL 
(n = 83 in a single increasing dose study [SAD]; 
n = 56 in the multiple dose escalation study 
[MAD]), they were randomized 3:1 to evinacumab: 
placebo. SAD patients received evinacumab sc at 
a dose of 75/150/250 mg or iv at a dose of 5/10/20 
mg/kg, monitored up to 126 days. MAD patients 
received evinacumab sc in doses of 150/300/450 
mg once a week, 300/450 mg every 2 weeks or 
iv at a dose of 20 mg/kg once every 4 weeks to 
56 days after 6 months of observation. There was 
a dose-dependent decrease in TG plasma concen-
tration, with a maximum reduction of 76.9% on day 
3 at 10 mg/kg iv (p < 0.0001) in SAD and 83.1% 
on day 2 when intravenous 20 mg/kg once daily 
4 weeks (p = 0.0003) in MAD. Significant reduc-
tion of other lipids was observed at most doses of 
evinacumab compared to placebo [43]. Gaudet et al. 
[44] tested evinacumab in a group of 9 adults with 
familial hypercholesterolemia. Patients received 
evinacumab at a dose of 250 mg sc at the beginning 
and 15 mg/kg iv in the second week of the study. 
After 4 weeks of treatment, evinacumab reduced 
LDL plasma concentration by an average of 49 ± 
± 23% (range 25–90%), with an absolute decrease 
from baseline 157 ± 90 mg/dL (range 71–323). 
In addition, a significant –48% — decrease in 
apoB100, non-HDL and TG plasma concentrations 
has been demonstrated [44]. ANGPTL3 inhibitors 
are characterized by good efficacy in the treatment 
of patients with HoFH. Hovingh et al. [45] in 
a study of 9 patients with HoFH evaluated the ef-
fect of evinacumab on LDL plasma concentrations. 
Evinacumab was dosed as a single 250 mg sc injec-
tion at baseline and subsequently as 15 mg/kg iv 
at week 2. Two patients further received 450 mg 
sc at weeks 12, 13, 14, and 15. The primary end-
point was the mean percent change in LDL plasma 
concentrations from baseline to week 4. The mean 
baseline LDL plasma concentration was 376 mg/dL. 
After 4 weeks of evinacumab therapy, LDL plasma 
concentrations decreased by an average of 49.2%. 
The maximum reduction in LDL plasma concentra-
tion ranged from 33% to 90%. It has been found 
that these preliminary results give great hope that 
inhibition of ANGPTL3 by evinacumab is likely to 
result in a clinically significant reduction in LDL 
plasma concentrations in patients with HoFH [45]. 
In another study by Banerjee et al. [46] which 
evaluated LDL receptor activity in HoFH patients’ 
lymphocytes before and after treatment with evi-
nacumab in comparison with the wild-type LDL 
receptor-positive lymphocytes, as well as in the 
LDL receptor defective Chinese hamster ovary cell 
line (CHO-LDLA7) transfected with plasmids en-
coding the LDL variant receptor. The overall mean 
maximum reduction in plasma LDL concentration 
with evinacumab was –58 ± 18%, occurring be-
tween weeks 4 and 12. The mutations identified in 
9 patients were shown to be pathogenic, with a loss 
of LDL receptor activity as compared to the wild-
type. Two of the LDL receptor variants (Cys681* 
and Ala627Profs*38, were type 2 mutations that 
are retained in the endoplasmic reticulum. Six 
variants are class 3 mutations with impaired LDL 
binding activity (Trp87Gly), occurred in 2 patients 
(Gln254Pro; Ser177Leu; Gly335Val; Ser306Leu). 
Evinacumab had no effect on LDL receptor activity. 
Researchers found that evinacumab is effective in 
lowering plasma LDL in HoFH patients, and inhib-
iting ANGPTL3 in humans reduces plasma LDL in 
a mechanism independent of LDL receptor [46].
Raal [47] during the American College of Car-
diology Congress in 2020 presented the results of 
a study involving 65 patients, 12 years of age or 
older with HoFH and plasma LDL concentrations 
greater than 70 mg/dL at screening. After an 
8-week lead-in period to stabilize basic lipid-lower-
ing therapy, 43 patients were randomized to receive 
evinacumab 15 mg/kg iv every 4 weeks and 22 to 
placebo group. Following a 24-week double-blind 
treatment period, there was a 24-week extension 
to the open label period during which all patients 
received the study drug. More than two-thirds of 
patients had some residual LDL receptor function 
— non-null/null genotype status — while about 
30% had minimal or no LDL receptor function — 
null/null genotype status. Over 90% of patients 
were taking a statin, over two-thirds were taking 
ezetimibe, about 20% were taking lomitapib, and 
just over one-third were taking apheresis. Despite 
these treatments, mean plasma concentrations of 
LDL and apoB100 in patients on entry were about 
250 mg/dL and about 170 mg/dL, respectively. 
Evinacumab has been shown to significantly reduce 
plasma LDL (by 47.1%), apoB100 by 36.9%, non-
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HDL cholesterol by 51.7%, total cholesterol by 
48.4%, and triglycerides by 50.4% (p < 0.0001 for 
all) concentrations. However, the study drug had no 
effect on Lp(a) plasma concentration (Table 1) [47].
Currently, six clinical trials using evi-
nacumab are underway in: healthy volunteers 
(NCT03146416), patients with persistent hyper-
cholesterolemia (NCT03175367), patients with 
HoHF (NCT03399786 and NCT03409744), chil-
dren with HoHF (NCT04233918) and patients with 
severe hypertriglyceridemia and high risk of acute 
pancreatitis (NCT03452228).
ANGPTL3-LRx
ANGPTL3-LRx are antisense oligonucleotides 
containing three GalNax residues which promote 
the specific recognition by hepatic ASGPR receptors 
(asialoglycoprotein receptor). Once internalized, 
ANGPTL3-LRx inhibit protein synthesis of ANG-
PTL3, respectively, by binding the corresponding 
mRNAs and inducing their degradation (Fig. 7) [34].
The use of ANGPTL3-LRx in healthy subjects 
aged 18-65 years with TG > 150 mg/dL (at doses 
of 10, 20, 40 and 60 mg/week for 6 weeks) resulted 
in a decrease in plasma TG concentration from 
33.2% to 63%, LDL by 1.3% to 32.9% and VLDL 
by 27.9% to 60% [37]. No side effects or serious 
adverse effects were noted, but clinical data are 
yet very limited [37].
There is currently insufficient information on the 
long-term safety of evinacumab and ANGPTL3-LRx. 
As both drugs are still in the early stages of de-
velopment, it has not yet been proven that the 
reduction in plasma LDL concentrations achieved 
with evinacumab and ANGPTL3-LRx will reduce 
cardiovascular risk, until there is clinical experi-
ence [33].
Conclusions
1. ANGPTL3, ANGPTL4 and ANGPTL8 play 
an important role in regulating lipoprotein 
metabolism. These proteins are involved in 
the regulation of triglyceride availability de-
pending on the nutritional status of the body.
2. Observational studies have shown that in-
creased plasma ANGPTL3, 4 and 8 concentra-
tions may reflect cardiovascular risk.
3. Observational studies have shown that low 
plasma concentrations of ANGPTL3, 4 and 8 
appear to reduce the risk of cardiovascular 
disease.
4. Animal studies have shown that reducing ANG- 
PTL3 activity leads to a decrease in plasma 
triglycerides, total cholesterol, VLDL, LDL 
and HDL concentrations.
5. The results of clinical studies indicate that 
the use of evinacumab and ANGPTL3-LRx is 
effective and safe in the treatment of patients 
with dyslipidemia and HoHF.
6. The lipid-lowering effect of evinacumab is 
independent of the type of LDL receptor 
mutation.
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